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Introduction {#sec005}
============

Reactive thrombocytosis (RT) refers to thrombocytosis in the absence of a chronic myeloproliferative disease or myelodysplastic disorder. RT is associated with various medical conditions including infections, inflammation, hemorrhage, trauma, or surgery \[[@pone.0237016.ref001]\]. RT can be either transient or sustained and is driven by increased production of thrombopoietin, catecholamines, and various interleukins (e.g. IL-6 and IL-11) \[[@pone.0237016.ref002]\].

Postsplenectomy RT is a very common event affecting 75--90% patients undergoing the splenectomy \[[@pone.0237016.ref003], [@pone.0237016.ref004]\]. The platelet counts after splenectomy usually increase 30--100%, with the highest values in the period between 10 to 20 days postoperatively \[[@pone.0237016.ref005]\]. Thrombocytosis may persist over the next 2--3 months in most cases but in a few patients, thrombocytosis persists indefinitely \[[@pone.0237016.ref006]\].

Although it is well established that the size and function of platelets in RT are normal and that their interactions with blood vessels remain qualitatively normal \[[@pone.0237016.ref001]\], RT has been occasionally associated with an increased risk of thrombotic and hemorrhagic events in patients undergoing splenectomy \[[@pone.0237016.ref007], [@pone.0237016.ref008]\]. The thrombogenic potential of RT following splenectomy in children without underlying hematological malignancies (myeloproliferative disorders or myelodysplastic syndromes) are still not clearly defined.

To clarify the incidence and short-term clinical course and possible complications related to RT following splenectomy in the absence of hematological malignancies, we provide a single institution experience with RT in the pediatric population undergoing elective or emergency splenectomy.

Patients and methods {#sec006}
====================

Patients and selection criteria {#sec007}
-------------------------------

The data of all patients who underwent total splenectomy (urgent or elective) at our pediatric surgical department between January 1999 and December 2018 were retrospectively reviewed. The following data were analyzed: Demographic parameters (age, sex), indications for surgery, operative procedures, preoperative and postoperative platelet count, the use of anticoagulant therapy, and postoperative complications. The patients were followed over the first three weeks postoperatively. According to indications for splenectomy and RT, the patients were divided into the non-neoplastic hematology group and the non-hematology group.

The inclusion criteria for both groups were (1) Patients aged \< 16 years; (2) Patients undergoing total splenectomy; (3) Development of postsplenectomy thrombocytosis with platelet count \> 500,000/μL; (4) Patients without neoplastic (myeloproliferative and myelodysplastic) hematological disorders.

All the clinical records were fully anonymized prior to the study. The Ethics Committee (Institutional Review Board) of University Clinical Center Sarajevo approved the study and waived informed consent request from the patients and their families (the number of approval: \#10-01-2-123/19).

Definitions and classifications {#sec008}
-------------------------------

Total splenectomy was defined as a complete surgical removal of the spleen. Myeloproliferative disorders were defined as any of several hematologic malignancies marked by the excess of one or more types of white blood cells \[[@pone.0237016.ref009]\]. These disorders include polycythemia vera, essential thrombocytosis, chronic myeloid leukemia (CML), and idiopathic myelofibrosis \[[@pone.0237016.ref009]\]. Myelodysplastic syndromes were defined as any of a broad group of bone marrow disorders that are characterized by an abnormal reduction in one or more lineages of circulating white blood cells due to defective growth and maturation of blood-forming cells in the bone marrow with a potential to progress to acute myelogenous leukemia (AML).

Thrombocytosis was defined as a platelet count \>500,000/μL. Mild thrombocytosis was defined as a platelet count \>450,000/μL and \<600,000/μL, moderate thrombocytosis a platelet count \>600,000/μL and \<1,000,000/μL, and extreme thrombocytosis as a platelet count \>1,000,000/μL. The platelets were consecutively measured first ten postoperative days after which three additional measurements (11^th^, 14^th^ and 21^st^ postoperative day) were done.

In an attempt to determine whether an association exists between RT and thrombotic or hemorrhagic complications, one month after hospital discharge all the patients were contacted for further investigations.

All platelet counts were performed on ABBOTT CELL DYN 3700 (Chicago, Illinois, USA) counter, using EDTA anticoagulated fresh blood. The normal range of platelet counts for this machine is 150,000 to 450,000/μL.

Statistical analysis {#sec009}
--------------------

To evaluate the normality of the distribution of continuous variables, we used the Shapiro-Wilk (SW) test. The student\'s t-test was used to compare independent continuous variables that followed the normal distribution. The Wilcoxon signed-rank test was used to test the differences of paired data without the normal distribution. *P*-values \< 0.05 were considered significant. All the statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) IBM Version 26 (SPSS) (UNICOM Systems, Inc.).

Results {#sec010}
=======

The characteristics of the cohort are summarized in [Table 1](#pone.0237016.t001){ref-type="table"}.

10.1371/journal.pone.0237016.t001

###### The patients' demographics, their perioperative characteristics, and indications for splenectomy.

![](pone.0237016.t001){#pone.0237016.t001g}

  Variable                                                                                               Overall     Indications for splenectomy   *P*-value    
  ------------------------------------------------------------------------------------------------------ ----------- ----------------------------- ------------ ------
  The number of patients no. (%)                                                                         52 (100%)   18 (34.6%)                    34 (65.4%)   \-
  Mean age at surgery (yr)                                                                               9.0±1.84    9.2±1.22                      8.6±2.08     0.12
  Sex (% male)                                                                                           37 (71%)    30 (81%)                      7 (19%)      0.09
  Preoperative platelet count                                                                            324 K/μL    332.5 K/μL                    317.5 K/μL   0.98
  Short-term adverse events (≤ 3 weeks) (wound infection, wound hematoma and splenic fossa collection)   4 (7.7%)    1 (5.6%)                      3 (8.8%)     \-

K/μL, kilo per microliter.

Fifty-two children with a mean age of 9.2 years (range, 0.6--14.5 years) had splenectomy at our institution in the period 1999--2018. All patients were treated with an open splenectomy approach and all received prophylactic antibiotics and pneumococcal vaccine. Among the splenectomy children, 37 (71%) were male and 15 (29%) female patients (male/female ratio of 2.5:1). Severe spleen trauma (rupture) was the most common indication for splenectomy (29 patients, 55.8%), followed by non-neoplastic hematological disorders (18 patients, 34.6%). Three patients (5.8%) had splenectomy for splenic hydatid cysts, and two (3.8%) had splenectomy for multiple splenic abscesses. Among the patients with non-neoplastic hematological disorders, splenectomy was indicated for hereditary spherocytosis (HS) (n = 16) and immune thrombocytopenia (ITP) (n = 2). Four patients (7.7%) developed postoperative non-thrombotic complications including wound infection, wound hematoma and splenic fossa collection ([Table 1](#pone.0237016.t001){ref-type="table"}). None of the patients developed thrombotic or hemorrhagic complications during the follow-up period. Neither postoperative death nor subsequent fatal infections were observed in the cohort. Forty-nine patients (94.2%) developed a postplenectomy RT. The percentages of mild, moderate and extreme thrombocytosis were 48.9%, 30.7%, and 20.4%, respectively. The comparisons between RT patients in non-neoplastic hematology and non-hematology groups is shown in [Table 2](#pone.0237016.t002){ref-type="table"}. In the non-neoplastic hematology group of patients, a gradual increase in platelet count was observed from the first to sixth day after splenectomy. After this period, the platelet count was gradually decreasing ([Table 3](#pone.0237016.t003){ref-type="table"}). In the non-hematology group of patients, the platelet count decreased in the first two days after splenectomy, probably because of hemodilution but gradually increases starting at day three. From the sixth to the eleventh day, RT has been reported in this group of patients, followed by a gradual decrease in the platelet count, but RT persisted three weeks following splenectomy ([Table 3](#pone.0237016.t003){ref-type="table"}). Although the recorded platelet counts were greater and lasted longer in the non-hematological group compared with the non-neoplastic hematological group, the difference was not significant (p = 0.21). Given that the international normalized ratio (INR) values were normal in all patients with extreme RT, the majority of the patients with extreme RT (80%) did not receive any antiplatelet or anticoagulant therapy. Only two patients received the treatment; one child received a low‐dose aspirin (5 mg/kg) until their platelet counts fell to the reference values while the older pubertal child received a subcutaneous enoxaparin treatment.

10.1371/journal.pone.0237016.t002

###### The comparative analysis of various clinical parameters between the two groups of the patients affected by reactive thrombocytosis.

![](pone.0237016.t002){#pone.0237016.t002g}

  Variable                                                                    Overall         Postplenectomy reactive thrombocytosis                     
  --------------------------------------------------------------------------- --------------- ---------------------------------------- ----------------- ------
  The number of patients no. (%)                                              49 (100%)       16 (32%)                                 33 (68%)          \-
  Mean age at surgery (yr)                                                    9.0±1.9         9.3±1.3                                  8.6±2.11          0.85
  Sex (% male)                                                                35 (71%)        29 (82%)                                 6 (18%)           0.08
  Preoperative leukocyte count                                                12.54x10^9^/L   9.43 x 10^9^/L                           13.42 x 10^9^/L   0.13
  Preoperative platelet count                                                 329             333                                      325               0.91
  Postoperative leukocyte count (K/μL)[\*](#t002fn002){ref-type="table-fn"}   12.21x109/L     11.4 x 10^9^/L                           12.48 x 10^9^/L   0.52
  Postoperative platelet count (K/μL)[\*](#t002fn002){ref-type="table-fn"}    716             586                                      846               0.47
  Mild thrombocytosis no. (%)                                                 24 (48.9%)      10 (42%)                                 14 (58%)          \-
  Moderate thrombocytosis no. (%)                                             15 (30.7%)      4 (26%)                                  11 (74%)          \-
  Extreme thrombocytosis no. (%)                                              10 (20.4%)      2 (20%)                                  8 (80%)           \-
  Length of stay (day)                                                        9.7             10.6                                     10.4              0.89

K/μL, kilo per microliter.

\*The presented numbers are mean values that were recorded for these variables in the first 21 postoperative days.

10.1371/journal.pone.0237016.t003

###### The comparison of platelet counts between the non-neoplastic hematology *vs*. non-hematology group.

![](pone.0237016.t003){#pone.0237016.t003g}

                                                                 Postplenectomy days                                                                           
  -------------------------------------------------------------- --------------------- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- -----
  Platelet count in the non-neoplastic hematology group (K/μL)   294                   347   384   448   479   609   675   502   505   511   497   485   460   420
  Platelet count in the non-hematology group (K/μL)              343                   314   322   378   376   497   619   749   951   974   985   992   760   665

K/μL, kilo per microliter.

Discussion {#sec011}
==========

It is well known that the incidence of thrombocytosis shows an age-dependent pattern with the highest reported occurrence in infants aged up to 24 months \[[@pone.0237016.ref010], [@pone.0237016.ref011]\]. Specifically, during childhood, platelet counts greater than 500,000/μL may be seen in 13% of neonates at birth, 36% during the first month, particularly in low birth-weight infants, and 13% in 6 to 11 months of age \[[@pone.0237016.ref011]\]. The trend of a gradual decrease in platelet counts continues throughout childhood and reaches normal levels by the age of 11 \[[@pone.0237016.ref011]\]. Thrombocytosis in children is caused by the immaturity of their innate and/or adaptive immunity or more frequently by infections \[[@pone.0237016.ref012]\]. We found no statistically significant difference in the age of children with RT because splenectomized children in our cohort were on average older (9.2 years) and because of the cause of thrombocytosis itself.

RT in childhood is usually associated with bacterial or viral infections; less frequent causes include anemias (hemolytic or iron-deficiency), autoimmune diseases, cancers and drugs \[[@pone.0237016.ref011]\]. Since the spleen in healthy persons is a reservoir for approximately 1/3 of total body platelets, splenectomy is a well-recognized cause of RT \[[@pone.0237016.ref003], [@pone.0237016.ref005], [@pone.0237016.ref013], [@pone.0237016.ref014]\]. Our study revealed a very high (94%) prevalence of RT among the pediatric population undergoing splenectomy. Although this prevalence appears to be high, it is in line with the previous studies that have been reported in pediatric population \[[@pone.0237016.ref001], [@pone.0237016.ref003], [@pone.0237016.ref004], [@pone.0237016.ref013], [@pone.0237016.ref014]\]. In addition, splenectomy was found to be one of the main causes of extreme RT \[[@pone.0237016.ref015]\]. In our study, the extreme thrombocytosis accounted for 20% of all reported cases of postsplenectomy RT.

Another important finding from our study is a higher incidence of RT including extreme RT in male patients, with the male/female ratio 2.5:1, which is in agreement with the previous studies \[[@pone.0237016.ref016]--[@pone.0237016.ref018]\]. The reasons for male predominance can be partially explained by the synergistic effects of sex hormones, especially androgens, on thrombopoiesis and androgen modulation of platelet count and function \[[@pone.0237016.ref019]\].

Extreme thrombocytosis may predispose several complications including neurological (vasomotor), thrombotic, and hemorrhagic \[[@pone.0237016.ref020]\]. However, in case of postsplenectomy RT, the platelets retain their normal structure and function, the bone marrow is normal, and the interaction of platelets with the vessel wall remains normal. Therefore, the association of thrombocytosis with complications such as thrombosis and hemorrhage appear to be related to quantitative rather than qualitative platelet abnormalities \[[@pone.0237016.ref001], [@pone.0237016.ref020]\]. This was also confirmed in our study given that the measured INR was normal in all cases including extreme RT. However, thrombotic complications have been occasionally reported in pediatric RT following splenectomy for other reasons \[[@pone.0237016.ref021], [@pone.0237016.ref022]\].

Some observations suggest that leukocytosis may also increase the risk of thrombosis in patients with myeloproliferative disorders \[[@pone.0237016.ref023]\], but no such association was found in patients without myeloproliferative disorders. Among our patients, there were no cases of clinically suggestive thrombosis including cases of portal splenic vein thrombosis (PSVT).

Previous studies have suggested that fatal thrombotic complications in adult patients with postplenectomy thrombocytosis can be prevented by prophylactic anticoagulants or antiplatelet drugs \[[@pone.0237016.ref024]\]. In contrast, studies that are more recent have shown a much lower rate of thrombotic events in postsplenectomy adult patients, which did not differ significantly compared to other postoperative groups \[[@pone.0237016.ref025]\]. The exceptions are patients with myeloproliferative neoplasms in whom platelets are often morphologically and functionally abnormal with the consequent increased risk of thrombosis and bleeding \[[@pone.0237016.ref026]\].

The treatment of asymptomatic infants and children with extreme RT is still controversial. However, 80% of children with extreme RT in our study did not receive any antiplatelet or anticoagulant therapy and had no any adverse event. These findings further support previous studies that revealed a low risk of complications among this population \[[@pone.0237016.ref001], [@pone.0237016.ref027]--[@pone.0237016.ref029]\].

Our study has several limitations including its retrospective nature, single center experience and small sample size. A longer follow-up period would provide valuable information on potentially late thrombotic events among the postplenectomy children with persistent RT. In addition, a postoperative ultrasound scans were not part of the routine checkups for occult splenic and portal vein thrombosis, which may affect these patients \[[@pone.0237016.ref022]\]. Despite all the limitations, we confirm that RT is a very common event following splenectomy, but in this study it was not associated with clinically evident thrombotic or hemorrhagic complications in children undergoing splenectomy for trauma, structural lesions or non-neoplastic hematological disorders.

AML

:   Acute myelogenous leukemia

CML

:   Chronic myeloid leukemia

HS

:   Hereditary spherocytosis

IL

:   Interleukin(s)

INR

:   International normalized ratio

ITP

:   Immune thrombocytopenia

PSVT

:   Portal splenic vein thrombosis

RT

:   Reactive thrombocytosis

SW test

:   Shapiro-Wilk test
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Reviewer \#1:

This is a retrospective single institution review of 52 pediatric open splenectomies, divided into non-hematologic (n=34) and hematologic non-neoplastic (n=18) indications. Ninety four percent of the sample developed post-splenectomy thrombocytosis but no thrombotic complications were reported.

The article is generally well written. However, important data are missing and the conclusion that post-splenectomy reactive thrombocytopenia "...is not associated with thrombotic or hemorrhagic complications in children without underlying haematological malignancies" is inadequately supported by the data (see below).

1\. Severe spleen trauma was commonest indication for splenectomy (56%) -- this is surprising as \>90% of blunt pediatric splenic trauma can be successfully managed conservatively. Perhaps this was penetrating trauma?

ANSWER: Thanks for your comment. We agree with your statement that blunt pediatric splenic trauma can be successfully treated conservatively in most cases. Such conservative or non-operative approach has been applied at our institution for many years with excellent results. Penetrating trauma caused by shrapnel from unexploded ordnance from the war of the 1990s in our country was the cause of splenectomy in four children. These children had multiple injuries to the organ systems. In one child, a spleen injury was caused by a knife blade. However, the remaining 24 children who underwent splenectomy over a twenty-year period had serious splenic injuries that resulted in unsuccessful conservative treatment.

2\. What was the protocol for recording postoperative platelet counts? Table 2 values are not meaningful unless they refer to peak postoperative platelet counts and the accuracy of the data depends on the frequency of blood sampling. Presumably, the figures in this table are means?

ANSWER: You are correct; the presented numbers are mean values. We now added an "\*" with the legend that refers to these numbers. Regarding the protocol for postoperative platelet counts, these were recorded first ten postoperative days in a consecutive manner, after which three additional measurements were done (11th, 14th and 21st day). We now updated this in Materials and Methods (page 7, lines 137-138).

3\. There are no data on spleen size, which is a factor in postoperative thrombotic complications.

ANSWER: Thanks for bringing this important issue to our attention. We have not provided the spleen size info in the manuscript given that we have incomplete spleen size measurements and all were done preoperatively.

4\. Did any of the patients receive any postoperative anticoagulant or antiplatelet therapy? The discussion suggests that 20% of the extreme thrombocytosis group did receive treatment.

ANSWER: Two patients received the treatment; one child received a low‐dose aspirin (5 mg/kg) until their platelet counts fell to reference values while the older pubertal child received a subcutaneous enoxaparin. The results paragraph have been updated accordingly (page 9, lines 190-192).

5\. The authors only report clinically evident thrombotic complications. No routine postoperative ultrasound scans were performed to check for occult splenic and portal vein thrombosis (see Stringer MD, Lucas N. Thrombocytosis and portal vein thrombosis after splenectomy for paediatric haemolytic disorders: How should they be managed? J Paediatr Child Health. 2018;54(11):1184-1188).

ANSWER: Thanks for your suggestion. Although asymptomatic cases of acute postoperative splenic and portal vein thrombosis detected by Doppler ultrasound have been well documented in children, postoperative Doppler ultrasound scanning in children undergoing splenectomy due to hemolytic diseases has recently been introduced at our institution. For this reason, we were able to analyze the possible existence of only clinically evident cases of thrombotic complications. We addressed your concerns in our limitations of the study (page 12, lines 252-254).

6\. Figure 1 axis labelling is incomplete

ANSWER: We decided to remove the Figure 1 given your and the comment from another reviewer.

Reviewer \#2: Title:

Clinical course and short-term outcome of postsplenectomy reactive thrombocytosis in children without myeloproliferative disorders: A single institutional experience from a developing country

Outlines:

The authors conduct a retrospective review of 52 children aged younger than 16 years with postsplenectomy reactive thrombocytosis. They found postsplenectomy reactive thrombocytosis is not associated thrombotic or hemorrhagic complications in children without underlying hematological malignancies.

The following are some comments and questions for the authors:

1\. Page 8, line 170. The authors mentioned the platelet count decreased in patients in the non-neoplastic hematology group. But in Table 3, it was reversed. The platelet count increased in patients in the non-neoplastic hematology group after postsplenectomy day 1. Please clarify for the readers.

ANSWER: We have corrected it.

2\. Page 8, line 172-173. The authors mentioned that RT has reported in the non-neoplastic hematology group from 5th to 10th day. But in Table 3, thrombocytosis (\>500,000/uL) was observed from postsplenectomy day 3 to 9. Please clarify for the readers.

ANSWER: We have now corrected in the text.

3\. Page 9, line 175-176. The authors mentioned that maximal platelet count was recorded on the 14th day. But in Table 3, the highest platelet count in the non-hematology group is on postsplenectomy day 11. Please clarify for the readers.

ANSWER: We have corrected it in the text.

4\. I can't understand Figure 1. What does X-axis indicate? What does Y-axis indicate? How to interpret the relationship between INR and platelet count based on the present figure (only 2 points and 1 line)?

ANSWER: We decided to remove the figure 1 given your and the comment from another reviewer.

5\. Page 11, line 226. Please cite references about postsplenectomy thromboembolic complications in children.

ANSWER: The references have been added (refs\#21 and 22).

6\. There are several language flaws in the article needs to be polished further.

ANSWER: Thank you for your comment. We have done additional proofreading to make the manuscript fully compatible with academic English standards.
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Dear Dr. Vranic,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.
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I wish you could make appropriate response to the reviewer-1 comments. Decision will be made after your revision.

==============================

Please submit your revised manuscript by Aug 23 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.
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Chun Chieh Yeh, M.D., Ph.D.

Academic Editor
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Thanks to your appropriate response and revision to the reviewers\' comments. The reviewer-1 still raised a suggestion for minor revision. I wish you could consider and make appropriate response to this suggestion. Decision will be made based on your response. Thanks.
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1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed
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\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.
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The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.
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5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.
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Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have responded appropriately to my comments BUT their conclusions are based on just 52 patients and are invalid. They did NOT routinely use postoperative ultrasound assessment of the portal and splenic vein nor did they record data on spleen size.

Nevertheless, I think the article would be valid if the conclusions are changed in both the Abstract and Discussion.

The following is suggested:

"We confirm that RT is a very common event following splenectomy, but IN THIS STUDY IT WAS not associated with CLINICALLY EVIDENT thrombotic or hemorrhagic complications in children undergoing splenectomy for trauma, structural lesions or non-neoplastic hematological disorders."

Reviewer \#2: Thanks the authors for the revision. The manuscript looks better and more clear to me. I have no other comments.
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7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.
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**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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Reviewer \#1: The authors have responded appropriately to my comments BUT their conclusions are based on just 52 patients and are invalid. They did NOT routinely use postoperative ultrasound assessment of the portal and splenic vein nor did they record data on spleen size.

Nevertheless, I think the article would be valid if the conclusions are changed in both the Abstract and Discussion.

The following is suggested:

"We confirm that RT is a very common event following splenectomy, but IN THIS STUDY IT WAS not associated with CLINICALLY EVIDENT thrombotic or hemorrhagic complications in children undergoing splenectomy for trauma, structural lesions or non-neoplastic hematological disorders."

Answer: Thank you for your favorable comments.

We also agree with your observation and the conclusion in both the abstract and discussion paragraph has been revised accordingly (lines 51-4 and 248-51).

Reviewer \#2: Thanks the authors for the revision. The manuscript looks better and more clear to me. I have no other comments.

Answer: Thank you.
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Reviewers\' comments:

10.1371/journal.pone.0237016.r006

Acceptance letter

Yeh

Chun Chieh

Academic Editor

© 2020 Chun Chieh Yeh

2020

Chun Chieh Yeh

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

21 Jul 2020

PONE-D-20-07037R2

Clinical course and short-term outcome of postsplenectomy reactive thrombocytosis in children without myeloproliferative disorders: A single institutional experience from a developing country

Dear Dr. Vranic:
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